What MoonLake Immunotherapeutics's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 14 | 32 |
| Total trades | 14 | 40 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 40 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer | Jul 27 | Open-market sale · S | −1,100 | $20.00 | −$22K | 2,711,198 |
| Reich Kristian | Chief Scientific Officer | Jul 22 | Open-market sale · S | −2,448 | $20.00 | −$49K | 2,712,298 |
| Reich Kristian | Chief Scientific Officer | Jul 21 | Open-market sale · S | −50,000 | $20.02 | −$1M | 2,714,746 |
| Reich Kristian | Chief Scientific Officer | Jul 20 | Open-market sale · S | −43,700 | $20.09 | −$878K | 2,764,746 |
| Reich Kristian | Chief Scientific Officer | Jul 15 | Open-market sale · S | −16,105 | $20.01 | −$322K | 2,808,446 |
| Santos da Silva Jorge | Chief Executive Officer | Jul 10 | Open-market sale · S | −68,289 | $20.02 | −$1.37M | 2,774,893 |
| Santos da Silva Jorge | Chief Executive Officer | Jul 09 | Open-market sale · S | −33,936 | $20.01 | −$679K | 2,843,182 |
| Santos da Silva Jorge | Chief Executive Officer | Jul 01 | Open-market sale · S | −47,775 | $20.03 | −$957K | 2,877,118 |
| Bodenstedt Matthias | Chief Financial Officer | Jun 22 | Open-market sale · S | −39,120 | $22.04 | −$862K | 1,115,435 |
| Bodenstedt Matthias | Chief Financial Officer | Jun 18 | Open-market sale · S | −2,794 | $19.60 | −$54.8K | 1,154,555 |
| Reich Kristian | Chief Scientific Officer | Jun 17 | Open-market sale · S | −50,000 | $19.43 | −$972K | 2,824,551 |
| Bodenstedt Matthias | Chief Financial Officer | Jun 17 | Open-market sale · S | −15,082 | $19.68 | −$297K | 1,157,349 |
| Reich Kristian | Chief Scientific Officer | Jun 16 | Open-market sale · S | −50,000 | $18.70 | −$935K | 2,874,551 |
| Reich Kristian | Chief Scientific Officer | Jun 15 | Open-market sale · S | −50,000 | $18.89 | −$945K | 2,924,551 |
| Bodenstedt Matthias | Chief Financial Officer | May 11 | Open-market sale · S | −13,653 | $20.02 | −$273K | 1,172,431 |
| Bodenstedt Matthias | Chief Financial Officer | Apr 14 | Open-market sale · S | −2,426 | $19.56 | −$47.5K | 1,186,084 |
| Santos da Silva Jorge | Chief Executive Officer | Apr 13 | Open-market sale · S | −51,873 | $18.23 | −$946K | 2,924,893 |
| Bodenstedt Matthias | Chief Financial Officer | Apr 10 | Open-market sale · S | −1,925 | $19.51 | −$37.6K | 1,188,510 |
| Santos da Silva Jorge | Chief Executive Officer | Apr 10 | Open-market sale · S | −98,127 | $18.41 | −$1.81M | 2,976,766 |
| Bodenstedt Matthias | Chief Financial Officer | Apr 09 | Open-market sale · S | −85,870 | $18.94 | −$1.63M | 1,190,435 |
Loading...